Pregled bibliografske jedinice broj: 286632
Dctx/estm weekly therapy continued by vp-16/estm treatment in HRPC patients (GS>6)
Dctx/estm weekly therapy continued by vp-16/estm treatment in HRPC patients (GS>6) // Book of Abstracts, 16th International Prostate Cancer Update, Beaver Creek, Colorado / David E Crawford (ur.).
Denver (CO): University of Denver, 2006. str. 49-49 (poster, međunarodna recenzija, sažetak, ostalo)
CROSBI ID: 286632 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Dctx/estm weekly therapy continued by vp-16/estm treatment in HRPC patients (GS>6)
Autori
Tarle, Marko ; Kovačić, Ksenija ; Kraljić, Ivo ; Kusić, Zvonko.
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo
Izvornik
Book of Abstracts, 16th International Prostate Cancer Update, Beaver Creek, Colorado
/ David E Crawford - Denver (CO) : University of Denver, 2006, 49-49
Skup
16th International Prostate Cancer Update, Beaver Creek, Colorado, January 18-22, 2006.
Mjesto i datum
Beaver Creek (CO), Sjedinjene Američke Države, 18.01.2006. - 22.01.2006
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
HRPC; HRPC; docetaxel therapy; weekly or q3w; time to progression
(HRPC; PRPC; docetaxel therapy; weekly or q3w; time to progression)
Sažetak
Docetaxel applied with estramustine and/prednisone is the mostly chosen treatment in HRPC patients. The administration of dctx in weekly or q3w doses remains an unsolved question. At that time we found slightly better results during 6 cycles of weekly application of dctx according to monitoring data.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
